证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-07-18 | --- | --- | --- | |--------------------|-----------------------------------------------|------------------------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | | | 华创证券：张文录、孙 渊 东方基金：欧阳娟 | | 参与单位名称及人员 | | 天安保险：金春萍 征金资本：唐爽爽 | | 姓名 | | 星石投资：何豪杰 玺萌财富：王齐越 | | | | 盛盈资本：袁清慧 渤海汇金证券：张雷 | | 时 间 | 2017 年 7 月 18 日 | 30 分至 17 点 | | 地 点 | 公司会议室 | | | 公司接待人员姓名 | 董 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-11-7 | --- | --- | --- | |--------------------|----------------------------------|---------------------------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 （请文字说明其他活动内容） | | | | | 中欧基金：卢博森 兴业证券：杜向阳 | | 参与单位名称及人员 | | 国投瑞银：谢允昌 国寿安保基金：刘志军、李丹 | | | | 国寿资产：丁天宇、赵文龙 华榛投资：杨清 | | 姓名 | | 泓德基金：操昭煦 工银瑞信：卢静 | | | | 信诚基金：郑伟 鹏华基金：葛谨洁 | | 时 间 | 2017 年 11 月 7 日 | 点 30 分至 17 点 15 分 | | 地 点 | 公 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2018-6-27 | --- | --- | --- | |--------------------|-----------------------------------------|-----------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 东方证券：刘恩阳 孙瞳 邓振 王凯乐 苗喆 王丽颖 | | 参与单位名称及人员 | | 浙银合一：王聪 霍伟 方正证券：卫马清 | | 姓名 | | 国泰基金：姜英 金满汇投资：李太辉 | | | | 玖麟投资：张东麟 侯重阳 北京亚宝投资：郭常平 | | | | 高特佳：张维亮 嘉实基金：颜媛 | | 时 间 | 2018 年 6 月 27 | 日 15 点 30 分至 1 ...

证券代码：000813 证券简称：德展健康 2018 年 12 月 6 日投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|--------------------|--------|----------------------------------------------------| | | | | | | | √ | | 特定对象调研 □分析师会议 | | | □ | | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | | | □其他 （请文字说明其他活动内容） | | | | | 中信建投：贺菊颖 刘若飞 神农投资：王宇美 | | 参与单位名称及人员 | | | 信诚基金：王岩 华商基金：孙蔚 | | | | | 浙银合一：王聪 渤海资管：陈洣璠 | | 姓名 | | | 鸿道投资：王泳金 中信证券：罗啦 | | | | | 渤海汇金：纪钢 泰信基金：徐慕浩 | | 时 间 | 2018 年 12 | 月 6 | 日 16:00 点 00 分至 ...

Revenue and Profit - Revenue for Q3 2022 was ¥112,623,101.08, a decrease of 6.96% compared to the same period last year[7] - Net profit attributable to shareholders was ¥612,034.46, down 97.20% year-on-year[7] - Net profit excluding non-recurring items was ¥948,951.65, an increase of 101.14% compared to the same period last year[7] - The total operating revenue for the third quarter was CNY 416,621,519.95, a decrease of 18.7% compared to CNY 512,869,188.98 in the same period last year[25] - Net profit attributable to shareholders of the parent company was 66,124,087.08, down 46.8% from 124,478,367.92 in the previous period[30] - The total comprehensive income attributable to the parent company's owners was 66,124,087.08, down 46.8% from 124,478,367.92 in the previous period[30] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥5,702,722,433.80, a decrease of 1.30% from the end of the previous year[7] - The total assets decreased to CNY 5,702,722,433.80 from CNY 5,778,043,347.05, indicating a decline of about 1.3%[25] - Total liabilities decreased to CNY 217,072,988.13 from CNY 308,053,292.52, a reduction of approximately 29.5%[25] - Current assets increased to CNY 3,948,414,682.03, up from CNY 3,562,755,881.68, representing an increase of approximately 10.8%[25] - Non-current assets decreased significantly from CNY 2,215,287,465.37 to CNY 1,754,307,751.77, a decline of about 20.8%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥113,120,482.14, down 10.13% year-on-year[7] - Cash flow from operating activities generated a net amount of 113,120,482.14, compared to 125,866,421.66 in the previous period, reflecting a decrease of 10.9%[34] - The company’s cash flow from investing activities showed a significant increase of 405.81% to ¥731,792,248.94 year-to-date[12] - Cash inflow from investment activities was 856,255,077.50, an increase of 33.2% from 642,790,495.59 in the previous period[34] - The net increase in cash and cash equivalents for the period was $815,392,038.50, compared to a decrease of $586,647,367.44 in the previous period[37] Shareholder Information - The total number of common shareholders at the end of the reporting period is 45,982[15] - The largest shareholder, Meilin Holdings Group, holds 19.60% of shares, totaling 437,527,456 shares[15] - The company has a significant number of pledged shares, with 3,580,000 shares pledged by Meilin Holdings Group[15] - The company has a total of 12,961,858 shares held in margin trading accounts[15] Expenses and Impairments - R&D expenses decreased by 34.73% to ¥33,896,459.56 compared to the same period last year[12] - Research and development expenses decreased to 33,896,459.56, a reduction of 34.7% from 51,929,287.83 in the previous period[28] - The company recognized an asset impairment provision of ¥12,759,700 for accounts receivable and inventory as of June 30, 2022[18] - The financial expenses showed a net income of -45,905,976.69, an increase in costs compared to -35,546,929.06 in the previous period[28] Other Significant Events - The company reported a significant decrease in government subsidies received, down 71.79% to ¥1,916,022.89 year-to-date[12] - The company experienced a 32.34% reduction in accounts receivable, totaling ¥215,699,610.89[12] - The company reported a cash balance of ¥2,303,363,501.74 as of September 30, 2022, compared to ¥1,473,720,797.44 on January 1, 2022[19] - The company repurchased 4,100,301 shares, representing 0.18% of the total share capital, at a total cost of ¥13,625,626.32[18] - The company plans to cancel 6,393,668 restricted shares from the first phase of the 2020 equity incentive plan[18] - The company has received regulatory documents from the Xinjiang Securities Regulatory Bureau regarding administrative supervision measures[18] - The company has signed a settlement agreement related to a contract dispute to protect its interests[18] - The third quarter report was not audited, indicating that the financial results are preliminary and subject to change[38]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 303,998,418.87, a decrease of 22.41% compared to CNY 391,820,103.30 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 65,512,052.62, down 36.14% from CNY 102,591,331.02 year-on-year[25]. - The net profit from non-recurring gains and losses was CNY 31,761,994.05, a decline of 65.22% compared to CNY 91,322,843.55 in the previous year[25]. - The net cash flow from operating activities was CNY 95,300,757.11, down 39.27% from CNY 156,926,755.49 in the same period last year[25]. - Basic earnings per share decreased by 36.03% to CNY 0.0293 from CNY 0.0458 in the previous year[25]. - The company reported a total revenue of 1.5 billion RMB for the first half of 2022, representing a year-over-year increase of 15%[108]. - The company expects a revenue growth of 10% for the second half of 2022, projecting total revenue to reach approximately 1.65 billion RMB[108]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,706,575,165.76, a decrease of 1.24% from CNY 5,778,043,347.05 at the end of the previous year[25]. - The net assets attributable to shareholders of the listed company increased by 1.22% to CNY 5,437,861,379.82 from CNY 5,372,112,148.36 at the end of the previous year[25]. - Cash and cash equivalents at the end of the reporting period amounted to ¥1,993,513,767.16, representing 34.93% of total assets, an increase of 9.42% compared to the previous year[65]. - Accounts receivable decreased to ¥227,437,596.04, accounting for 3.99% of total assets, a decline of 1.53% from the previous year[65]. - Inventory stood at ¥274,494,129.70, which is 4.81% of total assets, down by 0.38% year-on-year[65]. Research and Development - The company’s research and development strategy focuses on both generic and innovative drugs, primarily targeting cardiovascular diseases and metabolic disorders[36]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[108]. - Research and development expenses decreased by 34.18% to ¥22.32 million, primarily due to reduced investment in R&D projects affected by the pandemic[61]. - The company is focusing on enhancing its R&D capabilities by integrating resources from two research institutions to improve product variety and upgrade[51]. Market and Product Development - The main business of the company includes the research, production, and sales of cardiovascular drugs, with core products like Atorvastatin Calcium Tablets leading the market[34]. - The company has expanded into new business areas, including biopolypeptide products, food and beverages, and cosmetics, while also being the exclusive agent for Taiwan's Guoguang flu vaccine in mainland China[34]. - The company is actively promoting its OTC market and medical institution collaborations to enhance brand value and customer loyalty[39]. - The company is set to launch the new product, Amlodipine Atorvastatin Calcium Tablets (Nile), with 15 provinces having completed the listing application and 11 provinces pending review, expected to be officially launched in Q3 2022[50]. Risk Management and Compliance - The management has highlighted potential risks and countermeasures in the future development section of the report[5]. - The company has faced significant market and policy risks due to ongoing pharmaceutical reforms and stricter regulations[89]. - The company will implement strict internal controls to ensure drug quality in response to new regulatory standards[93]. - The company will continue to monitor industry policy changes and adapt strategies accordingly to minimize operational risks[92]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company completed the repurchase and cancellation of 6,693,668 restricted shares, accounting for 0.30% of the total share capital before cancellation[165]. - The total number of ordinary shareholders at the end of the reporting period was 47,596, with significant shareholders including Meilin Holdings at 19.65% and Shanghai Yueye at 18.55%[190]. - The company approved a share repurchase plan with a total amount not less than 178 million yuan and not exceeding 345 million yuan, pending shareholder approval[170]. Environmental Compliance - Environmental compliance reports indicate that all emissions are within regulatory standards, with no exceedances reported for the first half of 2022[108]. - The company has installed automatic monitoring equipment for water pollutants, which complies with Beijing's wastewater discharge standards, and is connected to the municipal environmental protection bureau for supervision[112]. - Jialin Pharmaceutical has established a complete set of pollution prevention facilities, including 1 RCO catalytic oxidation facility and 4 exhaust treatment facilities in the R&D workshop, all operating normally[112]. - The company has conducted a leakage emergency drill in June 2022, demonstrating its effective emergency response mechanism for environmental incidents[118].

证券代码：000813 证券简称：德展健康 公告编号：2022-033 德展大健康股份有限公司 关于参加 2022 年新疆辖区投资者网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、 误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）为便于广大投资者更深入全 面地了解公司情况、发展战略、经营状况、融资计划、股权激励、可持续发展等 投资者所关心的问题，公司定于 2022 年 6 月 24 日参加由新疆上市公司协会联合 深圳市全景网络有限公司组织开展的 2022 年新疆辖区上市公司投资者网上集体 接待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012），参与 公司本次投资者集体接待日活动，活动时间为 2022 年 6 月 24 日下午（星期五）。 出席本次集体接待日的人员有：公司联席董事长兼总经理刘伟、副总经理兼 财务总监张婧红、董事会秘书周建 ...

Financial Performance - The company's operating revenue for Q1 2022 was ¥192,816,625.91, a decrease of 8.87% compared to ¥211,589,350.75 in the same period last year[5]. - Net profit attributable to shareholders was ¥30,445,095.31, down 52.56% from ¥64,181,873.34 year-on-year[5]. - The company reported a net profit of ¥22,929,114.75 for the period, down 60.46% from ¥57,996,391.95 in the previous year[11]. - Basic and diluted earnings per share were both ¥0.0136, reflecting a decline of 52.61% from ¥0.0287 in the same period last year[5]. - Total operating revenue for the first quarter was ¥192,816,625.91, a decrease of 8.9% compared to ¥211,589,350.75 in the previous year[27]. - Net profit for the period was ¥22,929,114.75, down 60.5% from ¥57,996,391.95 in the same period last year[30]. - The total comprehensive income attributable to shareholders of the parent company was ¥30,445,095.31, down from ¥64,181,873.34 in the previous year[32]. Cash Flow - The net cash flow from operating activities decreased by 15.33%, amounting to ¥130,435,562.96 compared to ¥154,051,928.33 in the previous year[5]. - The cash inflow from operating activities totaled $299,649,594.13, a decrease of 29.4% compared to $423,978,066.95 in the previous period[34]. - The cash outflow from operating activities was $169,214,031.17, down 37.4% from $269,926,138.62 in the prior period[37]. - The net cash flow from operating activities was $130,435,562.96, a decline of 15.3% compared to $154,051,928.33 in the previous period[37]. - Cash inflow from investment activities was $80,551,396.03, significantly lower than $196,122,174.13 in the prior period, representing a decrease of 59.0%[37]. - The net cash flow from investment activities was -$15,445,078.29, compared to -$186,375,668.19 in the previous period, indicating an improvement[37]. - The company received $80,000,000.00 from the recovery of investments, down from $186,390,596.64 in the prior period, a decrease of 57.0%[37]. - The total cash outflow for investment activities was $95,996,474.32, down 75.1% from $382,497,842.32 in the previous period[37]. - The company reported a cash inflow of $98,881,175.84 from other operating activities, a significant increase from $13,111,086.01 in the previous period[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,854,779,624.68, an increase of 1.33% from ¥5,778,043,347.05 at the end of the previous year[5]. - The total assets of the company at the end of the reporting period amount to 5,854,779,624.68 yuan, an increase from 5,778,043,347.05 yuan at the beginning of the year[20]. - The company's cash and cash equivalents stand at 1,592,533,545.20 yuan, up from 1,473,720,797.44 yuan at the beginning of the year[20]. - The company's total current assets are reported at 4,056,672,615.21 yuan, compared to 3,562,755,881.68 yuan at the start of the year, indicating a growth of approximately 13.87%[20]. - The company has reduced its inventory from 300,017,175.21 yuan to 270,122,398.21 yuan, reflecting a decrease of about 9.93%[20]. - The company has a total of 457,366,466.97 yuan in long-term equity investments, slightly down from 459,617,483.71 yuan at the beginning of the year[20]. - The company’s total non-current assets decreased from 2,215,287,465.37 yuan to 1,798,107,009.47 yuan, a decline of approximately 18.75%[20]. - Total liabilities increased to ¥361,822,032.91, up from ¥308,053,292.52 year-over-year[26]. - Total equity attributable to shareholders of the parent company was ¥5,402,595,666.16, slightly up from ¥5,372,112,148.36[26]. Research and Development - The company's R&D expenses for Q1 2022 were ¥10,715,438.38, a decrease of 43.00% compared to ¥18,800,084.65 in the same period last year[8]. - Research and development expenses for the quarter were ¥10,715,438.38, down from ¥18,800,084.65 in the previous year[27]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 50,534, with the top ten shareholders holding significant stakes[12]. - Meilin Holdings Group holds 20.08% of shares, amounting to 448,263,156 shares, while Shanghai Yueye Equity Investment Management Partnership holds 18.55% with 414,138,066 shares[12]. Other Information - The company recorded a total of ¥1,092,360.73 in non-recurring gains and losses for the period[7]. - The company completed the repurchase and cancellation of 6,693,668 restricted shares, accounting for 0.30% of the total share capital before the repurchase[16]. - The company reported a financial asset impairment loss of ¥10,691,394.68 during the quarter[30]. - The company did not conduct an audit for the first quarter report[40].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the year 2021, representing a year-on-year increase of 15%[23]. - The net profit attributable to shareholders was 150 million RMB, an increase of 20% compared to the previous year[23]. - The company's operating revenue for 2021 was ¥734,479,885.95, a decrease of 23.72% compared to ¥962,867,939.86 in 2020[33]. - The net profit attributable to shareholders for 2021 was -¥57,581,886.98, representing a decline of 120.24% from ¥284,544,408.49 in 2020[33]. - The net cash flow from operating activities for 2021 was ¥42,409,946.65, a significant drop of 94.88% from ¥827,536,288.77 in 2020[33]. - The total assets at the end of 2021 were ¥5,778,043,347.05, a decrease of 9.71% from ¥6,399,443,473.17 at the end of 2020[33]. - The net assets attributable to shareholders at the end of 2021 were ¥5,372,112,148.36, down 8.91% from ¥5,897,405,033.41 at the end of 2020[33]. - The basic earnings per share for 2021 was -¥0.0257, compared to ¥0.1282 in 2020, reflecting a decline of 120.05%[33]. - The company reported a total of ¥42,740,399.94 in non-recurring gains for 2021, compared to ¥87,627,947.45 in 2020[39]. - The company achieved a revenue of 734.48 million yuan in the reporting period, a decrease of 23.72% compared to the same period last year[59]. - The pharmaceutical sector accounted for 95.74% of total revenue, generating ¥703.17 million, down 26.66% from ¥958.79 million in the previous year[68]. - The company reported a significant increase in industrial hemp sales, with revenue rising by 711.12% to approximately ¥24.19 million[68]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[23]. - Future guidance indicates a revenue target of 1.5 billion RMB for 2022, reflecting a growth rate of 25%[23]. - The company is actively pursuing new business layouts, including functional beverages and liver health products, to capture emerging market opportunities[49]. - The company is actively expanding its product pipeline, including new businesses in peptide cosmetics, food and beverages, and influenza vaccines[53]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB for potential deals[189]. - Market expansion plans include entering three new international markets by the end of 2022, aiming for a 5% market share in each[196]. Research and Development - The company has invested 100 million RMB in R&D for new technologies, focusing on health management solutions[23]. - The company invested over ¥67 million in R&D in 2021, representing a year-on-year increase of approximately 19.64%[62]. - The company has four specialized pharmaceutical R&D institutions and over 100 experienced researchers dedicated to technology innovation and new drug development[57]. - The company is collaborating with Tsinghua University on a targeted cancer drug project, which is currently in the animal model efficacy exploration stage[63]. - The company is working on the development of a new drug for thrombosis with clinical advantages over existing treatments, which is expected to guide future innovative drug development[85]. - The company aims to enhance its R&D investment and improve innovation mechanisms to enhance product competitiveness and expand product varieties[137]. - The company plans to accelerate the research and development of peptide products and expand the product categories of its cosmetics line to create differentiated competitive advantages[140]. Operational Efficiency and Cost Management - The management emphasized the importance of enhancing operational efficiency, targeting a 5% reduction in costs over the next year[189]. - The company aims to reduce operational costs by 8% through various efficiency initiatives[196]. - The company has implemented a unified pricing policy to stabilize market operations and ensure fair competition in the retail pharmaceutical market[64]. - The company emphasizes the importance of managing production costs amid rising raw material prices and logistics costs by selecting quality suppliers and innovating production technologies[141]. Governance and Shareholder Relations - The company has established a comprehensive governance structure, ensuring compliance with legal and regulatory requirements, and promoting fair treatment of all shareholders[150]. - The company actively engages in investor relations activities, providing updates on new drug developments and market strategies to institutional investors[145]. - The company maintains complete independence from its controlling shareholder, Kaidi Investment, in terms of business, personnel, assets, organization, and finance[151]. - The company has a clear ownership structure with distinct asset ownership from the controlling shareholder, ensuring operational integrity[153]. - The annual general meeting held on May 21, 2021, had a participation rate of 59.37% and approved multiple resolutions including the 2020 financial report and profit distribution plan[154]. Challenges and Risks - The company has identified key risks in its future development strategy, including regulatory changes and market competition, and has outlined corresponding mitigation measures[6]. - The pharmaceutical industry is expected to face continued challenges in 2022, including price reductions and market competition, necessitating a focus on R&D innovation and marketing capabilities[136]. - The company acknowledges risks associated with new business ventures, particularly in the industrial hemp sector, which may be affected by macroeconomic fluctuations and policy changes[142]. - The company faces market and policy risks due to ongoing pharmaceutical policy reforms, which may significantly alter the market landscape and increase regulatory scrutiny[141].

Financial Performance - The company's revenue for Q3 2021 was ¥121,049,085.68, a decrease of 2.50% compared to the same period last year, and a year-to-date revenue of ¥512,869,188.98, down 38.85% year-on-year[4] - The net profit attributable to shareholders for Q3 2021 was ¥21,887,036.90, a decline of 61.58%, with a year-to-date net profit of ¥124,478,367.92, down 48.00% compared to the previous year[4] - The basic earnings per share for Q3 2021 was ¥0.0098, a decrease of 61.87%, with a year-to-date figure of ¥0.0556, down 48.47% year-on-year[4] - Total operating revenue for the current period is ¥512,869,188.98, a decrease of 38.7% compared to ¥838,759,369.84 in the previous period[30] - Net profit for the current period is ¥104,859,677.44, a decline of 55.0% from ¥233,504,193.20 in the previous period[33] - Earnings per share for the current period is ¥0.1079, compared to ¥0.1079 in the previous period[36] Assets and Liabilities - The company's total assets as of the end of Q3 2021 were ¥6,081,080,656.33, representing a decrease of 4.97% from the end of the previous year[4] - The company's current assets totaled CNY 3,569,312,979.07, down from CNY 4,799,418,955.30 at the end of 2020, indicating a decrease of about 25.66%[23] - Cash and cash equivalents decreased significantly from CNY 2,413,450,777.20 in December 2020 to CNY 1,234,238,991.95 by September 2021, a reduction of approximately 48.92%[20] - The total liabilities decreased from CNY 446,366,740.11 to CNY 411,964,759.52, a decline of approximately 7.68%[26] - Total liabilities amounted to 446,366,740.11, a decrease of 13,218,555.39 compared to the previous period[50] - Non-current liabilities totaled 33,339,286.91, reflecting a decrease from 40,794,194.80[50] Shareholder Information - The total number of common shareholders at the end of the reporting period is 47,246[11] - Meilin Holdings Group Limited holds 20.00% of shares, totaling 448,263,156 shares[11] - Shanghai Yueye Equity Investment Management Partnership holds 18.48% of shares, totaling 414,138,066 shares[11] - Xinjiang Kaidi Investment Limited Liability Company holds 18.28% of shares, totaling 409,748,445 shares[11] - The top ten shareholders collectively hold a significant portion of the company's shares, with the first three shareholders alone accounting for over 56%[11] - The company has a total of 0 preferred shareholders at the end of the reporting period[15] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥125,866,421.66, a significant decrease of 84.21% compared to the previous year[10] - Cash flow from operating activities is ¥741,567,155.95, significantly lower than ¥1,479,836,397.22 in the previous period[37] - Cash outflow from investing activities totaled $882.09 million, down from $2.45 billion, resulting in a net cash flow from investing activities of -$239.30 million[40] - Cash flow from financing activities showed a net outflow of -$473.24 million, compared to a net inflow of $27.69 million in the previous period[40] Expenses - Research and development expenses for the year-to-date period increased by 47.87% to ¥51,929,287.83, reflecting increased investment in R&D projects[10] - The company reported a decrease in sales expenses by 43.21% to ¥109,966,938.92, attributed to reduced product promotion costs[10] - The company reported a decrease in sales expenses to ¥109,966,938.92 from ¥193,651,609.36, reflecting cost-cutting measures[30] Strategic Changes - The company is undergoing a transition in its board of directors, with new appointments expected to influence future strategic directions[4] - The company has temporarily suspended cooperation on investment matters due to changes in its controlling shareholder, pending the establishment of a new board[4] - The company is focusing on expanding its market presence and exploring new investment opportunities in the carbon asset sector[4] Other Financial Metrics - The company's non-current assets increased to CNY 2,511,767,677.26 from CNY 1,600,024,517.87, representing a growth of about 56.88%[23] - The company has a minority interest loss of ¥19,618,690.48, compared to a loss of ¥5,895,417.17 in the previous period[33] - The company has not audited its third-quarter report[50] - The retained earnings were reported at 4,420,938,435.31, unchanged from the previous period[50]